These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

684 related items for PubMed ID: 16735669

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
    van Schalkwyk E, Strydom K, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbröker D, Bardin PG.
    J Allergy Clin Immunol; 2005 Aug; 116(2):292-8. PubMed ID: 16083782
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
    Gross NJ, Giembycz MA, Rennard SI.
    COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Antoniu SA.
    Curr Opin Investig Drugs; 2006 May; 7(5):412-7. PubMed ID: 16729716
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].
    Tatlicioğlu T.
    Tuberk Toraks; 2008 May; 56(4):472-84. PubMed ID: 19123088
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.
    Field SK.
    Expert Opin Investig Drugs; 2008 May; 17(5):811-8. PubMed ID: 18447606
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
    Böhmer GM, Nassr N, Wenger M, Hünnemeyer A, Lahu G, Templin S, Gleiter CH, Hermann R.
    J Clin Pharmacol; 2009 Apr; 49(4):389-97. PubMed ID: 19318692
    [Abstract] [Full Text] [Related]

  • 18. Roflumilast for the treatment of chronic obstructive pulmonary disease.
    Rabe KF.
    Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.